Endocrine Abstracts

Background: Asprosin is a recently discovered hormone that plays a role in regulating glucose homeostasis and energy metabolism. It is produced in white adipose tissue and released into the bloodstream in response to fasting, stimulating the liver to produce glucose. Interleukin-6 (IL-6), a pro-inflammatory cytokine, is known to contribute to the chronic low-grade inflammation seen in obesity and type 2 diabetes mellitus (T2DM). It also plays a role in insulin resistance and impaired glucose metabolism. Adiponectin, on the other hand, is an adipokine with anti-inflammatory and insulin-sensitizing properties. Investigating the complex interactions and correlations among asprosin, IL-6, and adiponectin can deepen our understanding of the mechanisms contributing to insulin resistance and hyperglycemia in T2DM. This in turn may lead to the development of more targeted and effective therapeutic strategies for managing the condition.

Methods: A total of 75 patients (28 males and 47 females with a mean age of 54.4±7.5 years) with T2DM were recruited at the Department of Endocrinology of Kharkiv Regional Hospital. Chronic pancreatitis (CP) was diagnosed in 42 T2DM patients. IL-6, adiponectin and asprosin levels in blood serum were measured in all the study subjects by enzyme-linked immunosorbent assay.

Results: Our findings revealed a significant positive correlation between asprosin and IL-6 levels in patients with T2DM, both with and without CP. Additionally, we observed a negative correlation between adiponectin levels and both asprosin and IL-6 levels in patients with T2DM, with and without CP. Patients with CP showed significantly higher asprosin levels than those without CP (P<0,001).

Conclusions: These results suggest that there may be a potential interplay between asprosin, IL-6, and adiponectin in the context of T2DM and CP. Further studies are needed to elucidate the exact mechanisms underlying this correlation and to explore the potential therapeutic implications of targeting these molecules in the management of T2DM with and without CP.